Good MorningEquity markets closed out the first half of the year with a whimper. The S&P 500 gained less than 0.25% at the height of the session but did manage to set a new all-time high. The index gained a little bit more than 8% over the last three months and looks poised to set new highs again in the coming quarter. The risk for the market now is momentum. The MACD momentum indicator is diverging from the new high and suggests underlying weakness within the market. Without some new Catalyst to drive sentiment the risk of a market correction grows daily.
The next possible catalyst is Friday's NFP report. The June read of the ADP report suggests strong job creations in June if less than the expected 1 million new jobs. If the non-farm payrolls report echoes the sentiment the market will most likely move higher.
Featured: Sell these "safe" blue chips immediately (Ad) 
|
Consumer Discretionary | | There are always certain seasonal trends that impact markets throughout the year, and that is certainly the case during the summer months. Although the market tends to see less volume during this time period, there are still plenty of great buying opportunities that can reward investors who are cogn... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Markets | | Supply chain management solutions provider American Software (NASDAQ: AMSWA) stock is finally breaking as metrics improve. The supply chain management software provider has been a relative under-the-radar stock that has stayed under the $20 range for the majority of over a decade. The Company has be... Read the Full Story |
|
Technology | | Nvdia (NASDAQ: NVDA), 360 DigiTech (NASDAQ: QFIN) and Endava (NYSE: DAVA) are making investors the old-fashioned way: By earning institutional support.
One of the biggest market stories of the past year is the rise of the individual investor pushing so-called meme stocks higher. You might be forgi... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Markets | |
Let's skip the lengthy intro. The easiest way to lose money in the stock market: Timing the market.
Most day traders don't want to hear it. They plug their ears and continue to trade anyway. I know a day trader whose losses continue to mount but he keeps doing it anyway because well, he's addicte... Read the Full Story |
|
Markets | | Social media 3D gaming platform provider Roblox (NYSE: RBLX) stock has been a rollercoaster in 2021 climbing from a low of $60.50 in March to reaching highs of $103.87 in June 2021. Shares of the leading mobile gaming publisher in the U.S. are attempting a recovery off $78.56 recent lows. The Compan... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Consumer Staples | |
Constellation Brands Moves Up On Strong Results
Like so many other investment stories in the market today, Constellation Brands (NYSE: STZ) is a multi-faceted one. On the one hand, we have a company that's working hard to optimize its portfolio and position for long-term growth while on the other... Read the Full Story |
|
Markets | |
Bed Bath & Beyond Is Fundamentally A Good Buy
Bed Bath & Beyond (NASDAQ: BBBY) has popped up on our radar more than once over the past year and for more reasons than one. At the core of the story is a nationwide rationalization of the company that has it repositioned for growth. Add to th... Read the Full Story |
|
Healthcare | |
Moderna (NASDAQ:MRNA) was an unquestioned success stock in 2020. The company was one of the first to bring a vaccine candidate to the clinical trial stage. And it was second only to Pfizer (NYSE:PFE) to receive Emergency Use Authorization (EUA) for its mRNA vaccine.
MRNA stock is up a whopping ... Read the Full Story |
|
Consumer Discretionary | |
The Guidance Is Why We Like Barnes & Noble Education
The education industry, and Barnes & Noble Education (NYSE: BNED), have not had an easy time of it over the last year. The COVID-19 pandemic shut down not only the school systems but also extracurricular activities such as sports which ... Read the Full Story |
|
Consumer Discretionary | |
Nike (NYSE:NKE) got some serious air on Friday. On the strength of a stellar quarterly performance, the stock gapped up 15.5% to a fresh record high in more than six times the average volume.
The big leap propelled Nike from the back of the Dow-30 pack in 2021 and has helped the index to a 13.5% ... Read the Full Story |
|
The Early Bird Stock Of The Day Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California. | | View Today's Stock Pick |
|
